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Mycobacterial antigen MPT64 specific polyclonal antibody production and validation for 
an immunohistochemistry based diagnostic test for extrapulmonary tuberculosis  
Background: Tuberculosis (TB) is a major health problem, especially in low- and middle-income 
countries. Extrapulmonary TB (EPTB) constitute 20-40% of all TB. Diagnosis of EPTB poses 
challenges as the routine diagnostic tests are less sensitive due to the paucibacillary nature of the 
disease. Therefore, there is a need to develop better diagnostic tests for EPTB. An antigen detection 
test based on the detection of Mycobacterium tuberculosis complex specific protein MPT64 by 
immunohistochemistry (IHC) has been developed and validated in the routine diagnostic settings 
(1-8). These studies show that the MPT64 antigen detection test is applicable to various forms of 
EPTB, including HIV positive and HIV negative cases, on biopsies, fine-needle aspirates, and 
cytology smears with sensitivity 70-100% and specificity 65-100% which is significantly better 
than the routine tests. This test is robust, feasible to implement in high TB endemic settings (2), 
and can help in the timely and accurate diagnosis of EPTB, preventing empirical over-treatment, 
morbidity, and mortality. These findings warrant the large-scale implementation of the test. 
However, all these studies have been carried out by the limited amount of in-house rabbit 
polyclonal antibody (pAb). The reproduction of an anti-MPT64 antibody with applicability on IHC 
is a prerequisite for large-scale use of the test. Our research group has reproduced a monoclonal 
anti-MPT64 antibody which gives good reactivity with enzyme-linked immunosorbent assay 
(ELISA) against the recombinant antigen, but it does not give good reactivity on formalin-fixed 
tissues. This is probably due to variable epitopes in vivo and changes in the antigen during the 
fixation process. PAbs, by virtue of their polyclonality and heterogeneity, can bind to multiple and 
different antigenic epitopes, and could be a suitable candidate for IHC.  
Aims: The aim of this study was to reproduce the anti-MPT64 pAb, create a single batch in a large 
volume, validate the new pAb on formalin-fixed clinical samples, and compare the validity with 
Xpert MTB/RIF assay.  
Material and Methods: Recombinant MPT64 protein was prepared by using a mammalian cell 
expression system. Rabbits were used as host animals for the generation of pAbs. An immunization 
strategy was designed by a pre-immunization selection of 38/180 rabbits with minimal reactivity 
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of their sera on the formalin-fixed tissues by IHC. The 38 selected rabbits were immunized by 
recombinant antigen and Titer Max Gold adjuvant by using a shorter and longer immunization 
protocol generating 50 ml and 90 ml of sera, respectively from each rabbit. Individual bleeds from 
each rabbit were tested with ELISA and IHC. Sera with good reactivity by IHC on the formalin-
fixed TB positive control tissues and minimal reactivity on the non-TB tissues were further tested 
by making various cocktails to generate a single batch in a large volume. Various background 
reducing strategies were applied to achieve good specificity. These batches were tested on human 
clinical samples. The selected batch was validated on bacteriology confirmed (culture and/or Xpert 
MTB/RIF positive) EPTB (24 lymphadenitis and 21 pleuritis) and 41 non-TB biopsies by IHC. 
The sensitivity of the new pAb was compared with the microscopy for acid-fast bacilli and Xpert 
MTB/RIF assay using culture as a reference standard.   
Results: All bleeds had very good reactivity with ELISA, with titer mostly around 1:200.000. 
With IHC, reactivity with the individual bleeds was variable, some sera gave very good sensitivity 
and specificity, while others were less sensitive and/or less specific due to the non-specific 
background staining. Among the various background reducing strategies, overnight incubation of 
tissue sections with 3% bovine serum albumin and 10% normal goat serum followed by further 
blocking with serum-free protein block gave good results with a significant reduction of non-
specific staining. Among five cocktails made from sera of 25 rabbits, one cocktail consisting of 
sera from 10 rabbits gave the best results. The sensitivity of this cocktail was similar to the previous 
anti-MPT64 pAb, though the staining intensity was generally less, the signals were clearly visible. 
Using bacteriological confirmation as a reference standard, the sensitivity, specificity, positive and 
negative predictive values, and accuracy of IHC with this batch of new pAb in lymphadenitis were 
88%, 80%, 72%, 92%, and 83%, respectively, and in pleuritis were 86%, 80%, 69%, 92%, and 
82%, respectively. Using culture as a reference standard, the performance of the new anti-MPT64 
pAb was better than AFB microscopy in both lymphadenitis and pleuritis (sensitivity 88% vs. 
13%, and 89% vs. 6%), while it was better than Xpert MTB/RIF in the TB pleuritis (sensitivity 
89% vs. 17%) and similar to it in lymphadenitis (sensitivity 88% vs. 88%). 
Conclusion: The study shows that it is possible to reproduce pAbs that can detect the MPT64 
antigen in the formalin-fixed paraffin-embedded tissue sections by IHC. The sensitivity of the 
MPT64 antigen detection test by using these new pAbs is better than the AFB microscopy and 
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Xpert MTB/RIF. This opens up the possibility of the large-scale use of this test and its inclusion 
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1. Background  
1.1. Etiology and pathogenesis of tuberculosis 
Tuberculosis (TB) is potentially a preventable and curable infectious disease, which most 
commonly affects the lungs and causes pulmonary TB. However, any organ in the body can be 
involved, and the disease is then called extrapulmonary TB (EPTB). TB is caused by an acid-fast 
bacillus, Mycobacterium tuberculosis (MTB) that is first identified by Robert Koch in 1882. From 
a clinical and public health perspective, TB is divided into primary and post-primary (9). Primary 
TB occurs when the individual is infected with MTB for the first time without prior immunity to 
the infection. The infection progresses to a disease within a short time, usually 2 years, of the 
infection (10). However, more than 90% of the immunocompetent individuals can develop a 
protective immune response and restrict the infection leading to the formation of granuloma (11, 
12). Granuloma formation is an effective immune response mediated by adaptive immunity, which 
can control the infection but may not eradicate it completely (13). The mycobacteria may remain 
dormant as latent infection (10). Years later reactivation or reinfection in people who have 
developed immunity to primary TB, can result in post-primary TB disease, also known as adult- 
type or secondary TB (12, 14). Post-primary TB is characterized by the formation of cavities in 
the lungs, and contributes towards disease transmission and nearly 80% of all clinical disease (15). 
In high TB-endemic settings, primary TB is more common in children, while post-primary TB is 
more common in  adults (12). Reactivation of latent infection may be triggered by factors that 
compromise host immunity such as, Human immunodeficiency virus (HIV) coinfection, diabetes, 
alcoholic liver disease, malnutrition, and use of steroids or other immunosuppressive drugs (16). 
In high TB endemic countries when active disease occurs in later life, it becomes difficult to 
ascertain whether it is due to reactivation of latent infection or a new infection with another MTB 
strain. Patients suffering from active pulmonary TB are the primary source of transmission of 
infection via minute aerosol droplets through exhalation and expectoration (16). The World Health 
Organization (WHO) estimated that in 2017 nearly two billion individuals were infected with MTB 




1.2. Epidemiology of tuberculosis 
The global burden of TB is high and in 2018, ten million people were estimated to have TB, and 
approximately 1.5 million deaths from TB were  estimated  (18). TB is the ninth leading cause of 
death worldwide and the leading cause from a single infectious agent, ranking above HIV/AIDS 
(18). Of all TB infections, EPTB accounts for 20% and up to 50% in HIV patients (15). The annual 
incidence rates of EPTB has been increasing (15). 
Control of the global TB epidemic has so far failed due to the lack of effective vaccine, 
development of drug-resistant MTB strains, and the  lack of sensitive and rapid diagnostics for all 
forms  of TB (16). The WHO’s specific targets set in the End TB Strategy include a 90% reduction 
in TB deaths and an 80% reduction in TB incidence by 2030, compared with 2015, but TB 
incidence is falling slowly at about merely 2% per year, and there are still large gaps in case 
detection and treatment (18). Most deaths from TB could be prevented with early diagnosis and 
appropriate treatment. Better diagnostic tests for all forms of TB are needed to meet the targets of 
the End TB Strategy. 
1.3. Mycobacterium tuberculosis structure and proteins  
MTB is a pathogenic rod-shaped, non-motile bacterium. It is an obligate aerobe, non-spore 
forming, and facultative intracellular pathogen. MTB has waxy coating on its cell surface making 
the cells impenetrable to Gram staining (19). Therefore, acid-fast stains are used instead of Gram 
staining to identify MTB under microscope. MTB has a very slow replication time, about 18-58 
hours, and requires 3-4 weeks to produce visible colony on a culture medium (20). The cell wall 
consists mostly of lipids and carbohydrates, and it accounts for the major part of its virulence (21).  
Mycobacterial proteins are either somatic proteins of cell wall and cytoplasm or secreted proteins 
that are produced by active secretion during the growth of mycobacterium. Among 4000 
mycobacterial reported proteins, 376 are specific to MTB as they do not share homology with 
other proteins (22). Mycobacterial proteins filtrated from culture are mainly secreted proteins, but 
they also contain  cell wall and cytoplasmic proteins (23, 24). Previous studies have described 
different methods to differentiate between antigens that are actively secreted from the 
mycobacterial cell from intracellular (cell wall and cytoplasmic) during culture. One method is 
differentiation by localization index, which is based on the measurement of secretion efficiency of 
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MTB proteins and groups the proteins to either secretory or cytoplasmic. Cytoplasmic proteins 
have by definition a localization index of zero and secretory proteins determined in MTB culture 
fluids with minimal lysis are given values (23). Quantitative immunologic techniques like crossed 
immunoelectrophoresis have been used for quantification of individual MTB proteins in sonicates 
of washed bacilli and culture fluids, which allows the determination of a localization index and 
thereby help to differentiate between cytoplasmic and actively secreted (25). Various secreted and 
somatic mycobacterial proteins have been characterized by these methods (23, 25). Another 
method is studying the release of the enzyme isocitrate dehydrogenase from MTB during its 
growth as a marker of autolysis (26).  Five of the common mycobacterial secretory proteins 85a, 
85b, 85c, MPT51, and MPT64 are containing component-specific as well as cross-reacting 
epitopes, but MPT64 has less homology with other secretory mycobacterial proteins (27).  





Figure 1. Cells and molecules involved in the adaptive and innate immunity against MTB. 
 Adapted from: Javan MR, Jalali nezhad Aa, Shahraki S, Safa A, Aali H, Kiani Z. Cross-talk between the 
Immune System and Tuberculosis Pathogenesis; a Review with Emphasis on the Immune Based Treatment. Int J 




1.4.1.  Innate immune responses in tuberculosis 
Macrophages and neutrophils are the host’s first line of defense against MTB and they achieve 
their role of protection by phagocytosis and expression of antimicrobial peptides (28). When the 
MTB finds its way to a new host through inhaled airborne droplets nuclei and settles in the alveoli 
and finally pulmonary parenchyma, the early host response is an influx of phagocytic cells, which 
are the alveolar macrophages and recruited neutrophils (28). As the MTB infection is established 
in the lungs, the bacilli are phagocytosed by macrophages through receptor-mediated phagocytosis 
and also taken up by neutrophils and dendritic cells (DCs) (28). Growth of MTB can be controlled 
by activated macrophages but they cannot completely eradicate the pathogen neither in vitro nor 
in vivo (29). The main receptors on the surface of macrophage that involve in the entry of MTB or 
phagocytosis are complement receptors, mannose receptors, and scavenger receptors (30).  Several 
classes of pattern-recognition receptors are expressed by macrophages and involved in the first 
step of recognition of MTB (30).  
Neutrophils/granulocytes are permissive hosts for MTB, rapidly recruited to the site of infection 
that traffic MTB to draining lymph nodes (11). Lung neutrophils help to promote the adaptive 
immune response against MTB by delivering the pathogen to DCs in a form that makes them more 
efficient and faster in presenting the antigen to prime and activate naïve antigen-specific CD4+ T 
cells (31).  
MTB may modulate the immune response to its advantage by delivering signals through Toll-like 
receptors that can affect the innate immune susceptibility, lung pathology, immunopathogenesis, 
and cytokines production at the local site of infection (32).  
1.4.2. Adaptive immune responses in tuberculosis 
T and B cells constitute the adaptive immune response against MTB. These cells are activated by 
the MTB-infected macrophages and DCs of the innate immunity. DCs have a fundamental role in 
initiating an immune response against MTB but they are regulated at various checkpoints of the 
host immune response (33). They are the prime antigen-presenting cells that initiate the adaptive 
immune response by T cells against MTB (33). DCs start this complicated and slow process in 
interaction with apoptotic macrophages and neutrophils containing the MTB, which result in the 
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bacterial acquisition by DCs and earlier trafficking to lymph nodes and faster priming of T cells 
(33).  
Compared with other infections, the considerable delay in the onset of adaptive T cells immune 
responses in TB is well recognized and partly due to pathogen inhibition of apoptosis, delayed 
migration of dendritic cells from the lungs to the local lymph node, and influence of regulatory T 
cells (Treg) and Interleukin (IL) 10 (34). 
 Protective immunity against MTB and delay of control of bacterial growth depends on the central 
mediators CD4+ T-cells of helper type 1 (Th1) that activate antimycobacterial activity in 
mononuclear phagocytes, an activation that is mediated by cytokines including Interferon-gamma 
(IFN-γ) and Tumor necrosis factor-alpha (TNF-α) (35, 36). Therefore, HIV patients with low CD4+ 
T cells are highly susceptible to TB (37).  CD4+ Th cells can be differentiated into Th1, Th2, Th17, 
and Treg cells. Th1 secrets cytokines like IFN-γ, TNF-α, IL-2, lymphotoxin, and granulocyte-
macrophage colony-stimulating factor, which increase the activation of Th1cells, CD8+ cytolytic 
T lymphocyte, and maturation and activation of macrophages/granulocytes (38). While Th2 cells 
produce cytokines like IL4, IL-5, IL-10, and IL-13, which stimulate B cells to produce antibodies 
, but at the same time, suppress the Th1 type of immune response (38). The Th17 cells produce 
cytokines like IL-17, IL-17F, IL-21, and IL-22, which are involved in the early phase of host 
defense after MTB infection through stimulation of defensin production that recruits neutrophils 
and monocytes to the site of inflammation (38). Differentiation of T cells is decided by different 
cytokines (38). Th1 cell development is promoted by IL-12, IL-18, and IFN-γ, while Th2 cell 
development is induced by IL-4, IL-5, and IL-13. Th17 cell differentiation is stimulated by low 
concentration of transforming growth factor-beta (TGF-β), IL-6, IL-22, and IL-23, while Treg cells 
differentiation is induced by IL-2 and high concentration of TGF-β (39, 40). TGF-β-induced Treg 
cells can be inhibited by IL-6, and in combination with TGF-β, promote Th17 cell differentiation 
(41). Regulatory mechanisms to control the inflammation, and CD4+ T cells in response to MTB 
infection, are necessary to inhibit host damage. Uncontrolled TNF-α and IFN-γ under conditions 
of infection can be unfavorable and damaging to the host (42).  
Treg cells expressing FoxP3 are increased in TB infection and inhibit the production of INF-γ by 
memory gamma-delta T cells in response to MTB infection (43).  The responsiveness of CD4+ T 
cells can be limited through downregulation by TGF-β, which leads to suppressing the effector-
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immune response (44). The balance between IL-10 and Treg cells on one side and INF-γ and TNF-
α on the other side may determine whether the immune system can eradicate MTB with minimum 
damage to the host. 
Although CD8+ T lymphocytes is now generally accepted to have a role in anti-MTB immunity, it 
cannot compensate for absence or low CD4+ T cells (15, 42). CD8+ are capable of immune 
protection by secreting granulysin, granzymes, and perforins to kill MTB-infected cells (45). 
Memory T cells are formed after that MTB find its way to human and when they encounter MTB 
antigen again they replicate quickly and produce many cytokines like IFN-γ, IL-2, TNF-α, 
lymphotoxin, and granulocyte-macrophage colony-stimulating factor (40).    
The immune response to MTB results in the formation of granulomatous inflammatory lesions at 
the site of infection. Epithelioid cell granulomas with multinucleated giant cells and central 
caseation necrosis is a defining lesion of TB (13, 46). It indicates a protective immune response 
mounted by the host. Granuloma formation is, however, not limited to TB and is taking part in the 
pathogenesis of a variety of inflammatory diseases like sarcoidosis and fungal infections. Thus, 
histology based on the granulomatous inflammation with necrosis is not specific for TB. 
1.5. Diagnostic challenges in extrapulmonary TB 
1.5.1. Clinical presentation  
Active EPTB has a heterogeneous range of clinical presentations and forms of disease and is 
regarded as a big imitator by clinicians (47). The non-specific clinical features overlap with other 
chronic diseases that often lead to diagnostic difficulty based on clinical features. The disease 
usually presents insidiously with non-specific and systemic features like fever, malaise, loss of 
appetite, weight loss, and night sweats (47).  The localized symptoms are depending on the site of 
disease and the organ involved. EPTB is more common in young children and HIV coinfected 
individuals (48). The most common form of EPTB is tuberculous lymphadenitis followed by 
tuberculous pleuritis (47). Other common forms of EPTB include bone TB, peritoneal TB, urinary 
tract TB, and meningeal TB. The clinical presentation is usually characterized by local signs and 
symptoms from the involved organs with or without systemic features (47). 
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Tuberculous lymphadenitis is characterized by multiple and painless enlarged lymph nodes, 
commonly affecting the lymph nodes in the anterior cervical triangle, sometimes with fistula to 
the skin. Tuberculous pleuritis is characterized by chronic unilateral pleural effusion presenting 
with pleuritic symptoms with or without systemic symptoms.   
1.5.2. Laboratory diagnosis of EPTB 
The demonstration of MTB either directly or indirectly is the cornerstone of the diagnosis of EPTB. 
The direct diagnostic methods based on the detection of MTB or its products have low sensitivity 
because of the paucibacillary nature of EPTB. The indirect methods are based on the hosts immune 
response and measurement of this response which have low specificity.  
1.5.2.1. Direct diagnostics methods  
1.5.2.1.1. Acid-fast bacilli microscopy 
Acid fastness is a unique feature of MTB and other mycobacterial species (49). Ziehl Neelsen 
staining method can demonstrate acid-fast bacilli (AFB) in both smears and tissues by direct 
microscopy when the bacterial load is more than 106 bacilli/g tissue (50). This stain makes AFB 
looks red/pink under microscope. Due to the paucibacillary nature of EPTB, the sensitivity of AFB 
microscopy is very low, between 0-40% depending on the site of EPTB (5, 6). Centrifugation of 
the samples and fluorochrome staining with ultraviolet microscopy can increase the sensitivity of 
microscopy by 10% (50, 51). The low sensitivity limits its diagnostic value even though it is  cheap, 
easy to perform, and quick (5, 6). In addition to the low sensitivity of AFB microscopy, it cannot 
distinguish between MTB and atypical mycobacteria.  
1.5.2.1.2. Culture methods 
Culture is the gold standard method for a definite diagnosis of EPTB. It is more sensitive than 
AFB microscopy as fewer bacilli (10-100 bacilli/ml of sample) are needed to detect and isolate 
MTB for further species identification and drug-susceptibility testing (52). Solid cultures, egg-
based or agar-based, are time-consuming, requiring 4-8 weeks. Liquid cultures as BACTEC 
system have 10 % better sensitivity than solid cultures and give rapid results within 2-4 weeks, but 
they are more expensive and need safe disposal of radioactive waste (53). Establishing of culture 
facilities need both skilled laboratory technician and advanced laboratory facilities with 
appropriate biosafety conditions, which limits its availability in low-resource settings. The 
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sensitivity of culture in EPTB is poorer as compared to pulmonary TB and vary from 20-80% (54, 
55).  
1.5.2.1.3. Molecular methods 
Molecular methods based on nucleic acid amplification techniques (NAAT) have contributed to 
the development of tests like polymerase chain reaction (PCR) assays targeting different MTB 
genes (65 kDa, 38 kDa) or insertion sequences like IS-6110 which are in routine use. NAAT have 
higher sensitivity than culture methods as they can detect as few as 1-10 MTB bacilli in clinical 
samples and the results are available within 6-8 hours (56). NAAT can be performed on stored 
clinical samples either they are formalin-fixed or dried scraped material. In paucibacillary EPTB 
conventional PCR has low sensitivity, while nested and real-time PCR have higher sensitivity than 
AFB microscopy and culture (4-6). PCR assays are, however, very sensitive to contamination 
resulting in high false-positive results. This disadvantage has been overcome by the Xpert 
MTB/RIF automated molecular assay (GeneXpert). This assay is developed for the rapid detection 
of MTB and rifampicin resistance. The sensitivity of GeneXpert is heterogeneous and varies from 
25% to 96.6% depending on the site of EPTB (57). Lower sensitivities are reported in 
cerebrospinal, pleural, pericardial, peritoneal, and synovial fluids (58). The main limitation of the 
GeneXpert, as  a routine diagnostic test in EPTB, is high costs and lower sensitivity for smear-
negative than smear-positive clinical samples of EPTB (59). Furthermore, this assay cannot 
differentiate between viable and dead bacilli and cannot provide information about drug 
susceptibility other than rifampicin. 
1.5.2.1.4. Antigen detection tests 
Antigen detection methods have been introduced and studied in recent years. Antigen assay based 
on detection of mycobacterial Lipoarabinomannan (LAM) in urine has shown good performance 
in HIV-associated pulmonary TB with a high bacterial load, but is not useful in paucibacillary 
EPTB (60-62). Immunohistochemistry (IHC) and immunocytochemistry (ICC) based antigen 
detection tests have been reported with better sensitivity and specificity than AFB microscopy in 
various form of EPTB as it is capable to detect MTB antigens in both intact and degraded bacilli, 
while AFB microscopy detects only intact bacilli (4, 5). Various mycobacterial antigens can be 
detected in formalin-fixed paraffin-embedded tissue, tissue aspirate, and fluids, such as mixed 
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mycobacterial antigens, secreted MTB specific antigen MPT64 (1-8), antigen85 (63), ESAT6 (61), 
Cell wall-associated antigen5 (64), LAM (65), HspX (66), TB8.4, and phospholipase C encoding 
A (PLcA) protein (67). The advantage of IHC and ICC over PCR is that they are robust, not 
sensitive to contamination, and can be performed without high-tech equipment.  
1.5.2.2. Indirect diagnostic methods  
1.5.2.2.1. Histopathology and Cytology 
Due to the paucibacillary nature of EPTB, histological examination of specimens has been 
regarded as a method of choice for the diagnosis of EPTB (68). The presence of granulomatous 
inflammation with epithelioid cells, multinucleated giant cells, and caseous necrosis strongly 
suggest TB (68). However, several clinical conditions other than TB may cause the same 
granulomatous reaction such as fungal infections and sarcoidosis. Histological examination alone, 
therefore, might not lead to the correct diagnosis of TB (69). Furthermore, it is not possible to 
differentiate the various mycobacterial species on histological bases alone as the histological 
findings of tuberculous and non-tuberculous mycobacterial disease are the same. Fine needle 
aspiration cytology (FNAC) is recommended as first-line investigation in all accessible suspected 
EPTB as it is easy to perform, relatively cheap, rapid, and less invasive procedure (70). 
Tuberculous cytology pattern with the predominance of lymphocyte can be difficult to differentiate 
from other granulomatous non-tuberculous lesions and atypical TB lesions in advanced HIV 
disease. Therefore, explicit TB diagnosis on FNAC or body fluids is based only on bacteriological 
confirmation and that can only be achieved in 20-25% of EPTB cases (50).  
1.5.2.2.2. Serological tests 
Antibody-based serological tests like enzyme-linked immunosorbent assay (ELISA) for antibodies 
against MTB secretory protein superoxide dismutase are simple, inexpensive, and can be used as 
supplements to conventional methods to support the diagnosis of EPTB, but the negative test 
cannot exclude the diagnosis (71). In general, the serological tests have shown low specificity and 
poor reproducibility as the methods of purifying mycobacterial antigens are not reproducible (72). 
Therefore, they are not recommended in the diagnosis of TB in low- and middle-income countries 
(72). 
Tuberculin skin test used in screening for TB infection is a cellular immunity mediated test that 
measures the delayed hypersensitivity reaction (48-72 hours) after intra-dermal injection of 
20 
 
tuberculin antigen (73). The reagent used in this test is the MTB purified protein derivate. 
However, the limitation of the tuberculin skin test in the diagnosis of active EPTB is that positive 
test can also be caused by Bacillus Calmette-Guérin (BCG) vaccination or previous infection with 
MTB or non-tuberculous mycobacteria (74) . On the other hand, patients with immunosuppressant 
conditions can have false-negative results (75). 
An assay that measures interferon-gamma-release from the stimulated peripheral mononuclear cell 
in vitro is available as QuantiFERON TB Gold. This assay cannot differentiate between latent and 
active TB and thus have limited value as diagnostic tests to diagnose active EPTB, especially in 
high endemic areas in low- and middle-income countries (76). 
There is evidence that supports the use of measurement of enzyme adenosine deaminase activity 
in the diagnosis of EPTB. However, this assay is not specific for TB (77). 
Therefore, the lack of accurate and rapid diagnostic tests of EPTB remains one of the major 
challenges in the global control of TB.  
1.5.3. MPT64 antigen detection test 
Earlier studies in our laboratory have shown in-situ expression of nine different secreted and three 
somatic mycobacterial antigens, including MTB complex specific secretory antigen MPT64, by 
using IHC with in-house polyclonal antibodies (pAb) in various types of extrapulmonary 
paucibacillary TB lesions (63). These results have shown that MPT64 was consistently expressed 
intra-cellularly while other antigens were not detectable in the lesions where mycobacteria were 
below the detection limit of AFB microscopy and culture (63). This led to the hypothesis that 
MPT64 has a special ability of intracellular accumulation which makes it possible to detect it in 
lesions with only a small number of mycobacteria. An example is shown in figure 2, where MPT64 
antigen is seen as reddish-brown stain in the epithelioid cells and multinucleated giant cells of a 











Further work confirmed the hypothesis and led to the development of a diagnostic method based 
on the detection of this antigen by using immunochemistry on various biological fluids, lymph 
node aspirates, and biopsies (2, 3, 7, 8). These studies have shown that the assay can be applied to 
a wide range of clinical specimens from different geographical locations including Tanzania, India, 
South Africa, and Norway with significantly higher sensitivity and specificity as compared to the 
conventional methods of AFB microscopy and solid culture. The sensitivity and specificity of the 
assay are shown to be similar to nested-PCR (N-PCR) (1-8). The assay performs equally well in 
HIV co-infected TB cases with atypical histological features (1). Table1 shows the summary of 
studies on the MPT64 antigen detection test.  
  
a b 
Figure 2. IHC staining pattern of MPT64 antigen in (a) pleural and (b) lymph node TB lesions. MPT64 antigen 
is seen as reddish-brown stain in the epithelioid cells and multinucleated giant cells of a TB lesion, which is 
negative with acid-fast bacilli staining and culture.  
Picture (a) adapted from: Baba K, Dyrhol-Riise AM, Sviland L, Langeland N, Hoosen AA, Wiker HG, et al. 
Rapid and specific diagnosis of tuberculous pleuritis with immunohistochemistry by detecting Mycobacterium 
tuberculosis complex specific antigen MPT64 in patients from a HIV endemic area. Applied 
immunohistochemistry & molecular morphology : AIMM. 2008;16(6):554-61. 
 
Picture (b) adapted from: Mustafa T, Wiker HG, Mfinanga SG, Morkve O, Sviland L. Immunohistochemistry 
using a Mycobacterium tuberculosis complex specific antibody for improved diagnosis of tuberculous 
lymphadenitis. Modern pathology : an official journal of the United States and Canadian Academy of 





Table 1. Summary of studies on diagnostic validity of MPT64 antigen detection test in 
extrapulmonary tuberculosis. 
Author Country No. of 
cases 




























India 270 CSF, pleural, 
Acites, LN 
N-PCR 93/96 97/96 
Tadele et 
al. 2014 










Tanzania 152 Pleural, ascites, 
LN, CSF 
CRS 50-100 91-97 
Hoel et 
al. 2020 




CRS 37  99 
FOOTNOTE. No, Number; EPTB, extrapulmonary tuberculosis. IHC, immunohistochemistry; ICC, 
immunocytochemistry; LN, lymph node; CSF, cerebrospinal fluids; CRS, composite  reference standard; N-PCR, 
nested polymerase chain reaction; HIV, human immune deficiency virus. 
 
MPT64 antigen is present only in MTB complex and is not detected in non-tuberculous 
mycobacteria (78, 79) or in BCG strains with RD2 deletions (80, 81). In other words, the MPT64 
antigen detection test can differentiate between pathogenic and atypical mycobacteria. The test is 
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significantly faster compared to culture as the results are available within 1-4 working days 
depending on the sample type. These findings support the implementation of this test in a routine 
TB diagnostic setting. An ongoing multicenter study shows that the test is indeed implementable 
in the routine diagnostic setting of high TB endemic countries, and the performance of the test is 
better than the routine tests (3). The results from the other four sites are under analysis. These 
results support the view that the test should be made available for routine TB diagnostics globally. 
The uniqueness of the test is in the functional primary antibodies applicable on formalin-fixed 
material. Until now, all the studies have been carried out by the limited amount of in-house rabbit 
pAb. For further scale-up of the test, the reproduction of a functional antibody is the first and 
foremost prerequisite. 
Our research group has reproduced a monoclonal antibody (mAb) anti-MPT64 which gives good 
reactivity with ELISA against the recombinant antigen, but it does not give good reactivity on 
formalin-fixed tissues. This is probably due to variable epitopes in vivo and changes in the antigen 
during the fixation process. PAbs, by virtue of their polyclonality and heterogeneity, can bind to 
multiple and different antigenic epitopes, and could be a suitable candidate for IHC. 
2. Objectives 
2.1. Main objective 
The aim of this study was to reproduce an anti-MPT64 pAb for large-scale use on formalin-fixed 
clinical samples by using IHC.  
2.2. Specific objectives  
1. To design a strategy to produce a single batch in a large volume of functional anti-MPT64 
pAb for application on formalin-/alcohol-fixed samples. 
2. To validate the new pAb on clinical samples for diagnostic accuracy. 
3. To compare the validity of new pAb with Xpert MTB/RIF assay. 
3. Methods 
3.1. Preparation of the recombinant protein  
Recombinant MPT64 protein was prepared by the mammalian cell expression system. This system 
was chosen as it is able to introduce proper protein folding/posttranslational modifications ( such 
as phosphorylation and acetylation), which are usually crucial for the activity of target protein 
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(82). E-coli, commonly used to produce recombinant proteins, can have posttranslational 
modifications of the target protein which are different from those in mammalian cells and can 
affect its structure and activity. 
The target was MTP64 from Mycobacterium bovis (without signal sequence, with start M, linker, 




NPGELLPEAAGPTQVLVPRSAIDSMLAVLVPRGS AAALEHHHHHHHH * 
Complementary DNA (cDNA) was synthesized and ligated into a vector suitable for transient 
transfection. The expression vector was added to E. coli and the correct insertion was analyzed by 
sequencing. The preparation of plasmid was done by the cultivation of an E. coli strain harboring 
the expression vector. Plasmid DNA was controlled for low endotoxin. A functional coding DNA 
template was introduced into the mammalian cells through non-viral methods commonly called 
transient gene expression (TGE). Human embryo kidney (HEK) cells were used for protein 
expression. The transient transfection of HEK cells was done by cultivation in serum-free 
suspension culture. HEK cells were transfected 
with INVect Transfection Reagent (Figure 3).  
The principles of the TGE method is 
summarized in figure 3. 1) Plasmid DNA with 
the genetic information of MPT64 was 
expressed and is negatively charged. 2) INVect 
transfection reagent consists of polycationic 
polymers. 3) Polyplexes are positively charged 
particles and formed as a consequence of an 
electrostatic reaction between plasmid DNA 
and INVect transfection reagent. 4) Polyplexes 
interact with the negatively charged cell 
membrane and thereby internalized through receptors on the cell membrane by endocytosis. 5) 
Primary and secondary amine in the polyplexes protects plasmid DNA from degradation in the 
Figure 3. Summary of protocol of 
expression process. 
Adapted from InVivo BioTech Services 
GmbH. https://www.transient-




lysosome by preventing acidification of lysosome through proton adsorption leading to osmolality 
shift and the influx of water resulting in damage of lysosome. This is what referred to as the “proton 
sponge effect”. 6) Plasmid DNA enters the nucleus after it has been released from polyplexes 
through nuclear pores or during mitosis. 7) The gene of MPT64 is transcribed into mRNA by RNA 
polymerase. 8) Translation of mRNA takes place in ribosomes and the MTP64 protein is formed 
in lumen of endoplasmic reticulum. 9) MPT64 protein is transported from endoplasmic reticulum 
to Golgi apparatus where MPT64 is packed into secretory vesicles that move towards the cell 
membrane. 10) MPT64 is synthesized.  
The purification of protein was done by affinity chromatography. Dialysis was done against tris- 
buffered saline (TBS), pH 7.4. The expressed protein content was analyzed by SDS-PAGE which 
is an electrophoresis method that allows protein separation by a mass. MPT64 mas is 23 kDA. 
Charles River PTS Endosafe system was used to determine endotoxin. MPT64 protein was stored 
and delivered at 2-8 C. 
3.2. Adjuvant 
The commonly used adjuvant to enhance the immune response and thereby increase the production 
of pAb in immunization is Freund’s complete adjuvant, which we could not use as it contains 
mycobacterial components and it was not desirable with an antibody that has specificity against 
other components of MTB than the target antigen MPT64. Thus, two other adjuvants were tried. 
The first adjuvant was lipopolysaccharides of the blue-green algae Phormium species (Biogenes, 
Berlin, Germany). The second adjuvant was the Titer Max Gold adjuvant (TMGA) (Sigma-
Aldrich, Søborg, Denmark). The use of TGMA gave a better titer and was selected for 
immunization. TMGA is a type of water-in-oil emulsion. It contains three ingredients which are a 
block copolymer, CRL-8300, squalene (a metabolizable oil), and a unique microparticulate 




3.3. Strategy for immunization and pooling of sera 
 
Figure 4 shows the immunization plan. To minimize the non-specific reactivity, we adopted a 
strategy of testing the sera from several rabbits before immunization and selection of those rabbits 
with minimal or no reactivity by IHC. Among the 180 rabbits tested before immunization, only 38 
animals were selected for immunization. Each immunization was done with about 50 μg protein 
per kg per animal. Injections were carried out intradermally. Boosters were given at day 14, 28, 
and the test bleed was done at day 35 to confirm the specific reactivity of mycobacterial antigen 
with ELISA and IHC. The sera from 15 rabbits gave a very good specific reactivity with IHC. 
These rabbits were selected for a long immunization protocol to harvest larger serum volume. In 
this protocol, the booster was given at day 42, 63, and 84. At day 49 and 70 bleeds were performed 
to harvest 20 ml serum at each time point. The final bleed was done at day 90. In the rest 23 rabbits, 
the specific reactivity of test bleed was not very strong, and the immunization protocol was 
shortened to the booster on day 42 and final bleed at day 49. All the bleeds from each animal were 
tested again with ELISA and IHC. All sera were preserved by 0.02% Thimerosal and 15mM 
Figure 4. Immunization strategy and pooling of sera to make a functional polyclonal anti-MPT64 antibody.  
FOOTNOTE. N, number; IHC, immunohistochemistry; ELISA, enzyme-linked immunosorbent assay.  
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sodium azide. IHC was performed on a known TB and non-TB formalin-fixed paraffin-embedded 
biopsies. Sera from 13 rabbits were excluded due to unsatisfactory reactivity with IHC. Different 
dilutions were tried for each bleed and an optimal dilution was selected for each bleed (Table 2). 
The sensitivity varied among different bleeds. Further, five different cocktails were tried to make 
a single batch in a large volume. In cocktail 1, the sera from 55 bleeds of all 25 rabbits were mixed. 
Cocktail 2 was made by mixing the sera from only 8 bleeds of 4 rabbits that showed the best 
sensitivity and specificity on individual IHC testing. Cocktail 3 was made by combining the sera 
from 22 bleeds of 10 rabbits, that showed good sensitivity and specificity on individual IHC 
testing. In cocktail 4, the sera from 31 bleeds of 14 rabbits that gave good sensitivity, but relatively 
lower specificity were mixed. Cocktail 5 was made by mixing the sera from cocktail 3 and 4. All 
these cocktails were further tested with serial dilutions (Table 2).  
3.4. Enzyme-linked immunosorbent assay  
Test bleeds and final bleeds were tested with ELISA. Plates were coated with the recombinant 
antigen by overnight agitation of antigen in 0.05M carbonate buffer, pH 9.5 (100 µl/well) at room 
temperature. For blocking, wells were emptied and then incubated on a shaker with TBS 
containing 1% fetal calf serum (200 µl/well) for 30 minutes at room temperature. Wells were 
washed with TBS-TW (washing buffer tris)  (300 µl/well). Different dilutions of pre-immune sera 
and antisera were made in TBS-TW with 1% fetal calf serum. Dilutions were added in duplicate 
per well (100 µl/well) and incubated in a shaker for one hour at room temperature. TBS-TW with 
1% fetal calf serum was used as blank. Wells were washed four times with TBS-TW (250 µl/well). 
Then 100 µl/well anti-rabbit -1gG-POD (SigmaA4914), 1:20.000 diluted in TBS-TW, were 
incubated on a shaker for one hour at room temperature. Wells were washed again four times with 
TBS-TW. After that, wells were given 3,3’, 5,5’- tetramethylbenzidine ready to use substrate from 
Kem-En-Tac Diagnostic (100 µl/well). The enzymatic reaction was stopped after 15 minutes by 
adding 0.5M Sulfuric acid (100 µl/well). The absorption of the yellow solution was measured 
using a 12-channel photometer at 450 nm (reference wavelength 630 nm) 
3.5. Strategies to reduce the non-specific staining with immunohistochemistry 
One major challenge we faced was the non-specific staining (NSS). Several strategies were used 
to reduce the NSS. A known TB biopsy and a non-TB biopsy were used to evaluate the results.  
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First, antigen affinity purification of pAbs was tried to improve the specificity. The recombinant 
MPT64 antigen was coupled with Sepharose beads and these were utilized in column 
chromatography to bind the anti-MPT64 pAbs. Other unwanted serum proteins and 
immunoglobulins were washed away. MPT64 bound pAbs were released from the column by 
using the acidic solution. 
Secondly, sera with pAbs were absorbed overnight with the BCG Copenhagen vaccine strain 
which lacks the MPT64 gene to remove cross-reactive antibodies to other mycobacterial antigens 
than MPT64 as done previously (4). BCG sonicate was added to the undiluted sera with pAbs in 
1:5 ratio, vortexed gently, and left to stand at 4 degrees Celsius for a day. 
Thirdly, the sera with pAbs were absorbed with the formalin-fixed human lung and lymph nodes 
biopsy material. These tissues were selected because of the reactivity of the sera with pAbs with 
some structures in these biopsies. Non-TB lung and lymph nodes formalin-fixed, and paraffin- 
embedded biopsies were selected. About 10-µm thick sections were prepared from each biopsy 
and six sections from each biopsy were placed in a tube. These biopsies were hydrated by passing 
through xylene. The tissue sections were submerged in enough xylene, and vortexed to make sure 
that xylene was mixed with tissue sections. After ten minutes the tube was centrifuged, and the 
supernatant was removed. This step was repeated. Enough amount of series of declining 
concentration of alcohol (two times 100%, one-time 96% and 80%) was added to merge the tissue 
completely and then the tube was vortexed to make sure that alcohol was mixed with tissues. After 
three minutes, the tube was centrifuged, and the supernatant removed. The same step was repeated 
with distal water. The tissues were mixed with 1 ml of phosphate-buffered saline and lysed by 
using lysing matrix tube A (MPbio.com) which contains a garnet matrix and ¼ ceramic sphere and 
homogenized for 40 seconds by using Fastprep-24-5G homogenizer. This mix of beads and lysed 
tissue were added in the working dilution of antibodies in 1:1 ratio, vortexed, then incubated 
overnight in the refrigerator. The mixture was centrifuged, and the supernatant was used as the 
primary antibody. 
Fourthly, sections on the glass slide were incubated with different protein solutions before the 
addition of primary antibody such that these proteins will bind to the non-specific sites in the 
sample. Blocking with serum-free protein block (Agilent/Dako, Glostrup, Denmark), 3% bovine 
serum albumin (Sigma-Aldrich, Søborg, Denmark) and 10% normal goat serum (Agilent/Dako, 
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Glostrup, Denmark) were tried for different times (12 minutes, 60 minutes and overnight), and in 
various combinations.  
Fifthly, a human Fc block pure (Becton Dickinson, NJ, USA), which is a purified recombinant 
protein derived from immunoglobulin that reduces the binding of antibodies to Fc receptors, was 
tried in different dilutions. Dilutions were made by using the antibody diluent (Agilent/Dako, 
Glostrup, Denmark). Sections were incubated with this solution for 30 minutes after they were 
treated with a serum-free solution for two different durations of overnight and 15 minutes. Then 
the solution was taped off and the primary antibody was applied.  
Finally, we also tried diluting the sera with pAbs in the sodium thiocyanate solution, and betaine 
(Sigma-Aldrich, Søborg, Denmark) to prevent the weaker binding of pAbs.  Different dilutions of 
sodium thiocyanate and betaine were made by adding the defined volume of these solutions in the 
antibody diluent. The primary antibody was diluted in these mixtures of betaine/sodium 
thiocyanate and the antibody diluent.  
3.6. Immunohistochemistry  
Parallel, 4 µm thick sections were prepared from formalin-fixed, paraffin-embedded biopsy and 
cell blocks by using a sliding microtome, Leica RM 2155 microtome. The sections were placed on 
Superfrost PlusTM adhesion microscope slides and incubated at 58C in hot air oven for overnight. 
The slides were stored at 4C. 
The detection of MPT64 antigen in the tissue sections was done by using IHC. This technique is 
based on the principle of antibody binding to a specific antigen. IHC can detect antigens within 
tissues and thus provide important information about location in addition to the identification of 
the Antigen. IHC was performed using the En Vision + System-HRP (Agilent/Dako, Glostrup, 
Denmark). The sections were deparaffinized using xylene and then treated in a series of declining 
concentration of alcohol to remove xylene. Then the sections were placed in distilled water for 
rehydration. The sections were placed in a microwave for antigen retrieval using tris EDTA buffer, 
pH 9 (Agilent/Dako, Glostrup, Denmark) for 20 minutes. The purpose of the process of antigen 
retrieval is to help to expose the epitope, which may be hidden during formalin fixation of the 
tissues. The sections were left to cool for 20 minutes at room temperature. Tissue sections were 
washed using TBS, pH 7.6 (Agilent/Dako, Glostrup, Denmark).  Then pen (Agilent/Dako, 
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Glostrup, Denmark) was used to encircle the tissues region such that the reagent will be kept within 
the prescribed area. To inhibit the endogenous peroxidase activity and thereby reducing the non-
specific background staining, the sections were then incubated with hydrogen peroxide 
(Agilent/Dako, Glostrup, Denmark) for 20 minutes. The endogenous peroxidase will otherwise 
react with substrate (chromogen) leading to false-positive staining. After that, the sections were 
washed with TBS, they were incubated overnight with a combination of 3% bovine serum albumin 
and 10% normal goat serum followed by serum-free protein block for 12 minutes. This was done 
to prevent the non-specific binding of the antibody to the tissues. Primary pAbs in 1:400 dilution 
(new anti-MPT64 pAb) and 1:250 dilution (previous anti-MPT64 pAb) were applied to the 
sections for 60 minutes. The sections were again washed with TBS and incubated with secondary 
antibody, labelled polymer HRP anti-rabbit (Agilent/Dako, Glostrup, Denmark) for 40 minutes. 
The sections were washed with TBS, and then 3-amino-9-ethylcarbazole containing hydrogen 
peroxide substrate (Agilent/Dako, Glostrup, Denmark) was applied for 15 minutes to visualize 
bound antibody. On the positive tissue sample, 3-amino-9-ethylcarbazole gave rust-red colour. In 
the end, the background was counter-stained with Mayer’s hematoxylin for 1 minute 
(Agilent/Dako, Glostrup, Denmark), and the slides were mounted in Immu-Mount (Agilent/Dako, 
Glostrup, Denmark). 
IHC staining was controlled by using two negative and one positive controls. In one negative 
control, the primary antibody was substituted with antibody diluent. The second negative control 
was non-TB tissue. The positive control was previous in-house anti-MPT64 pAb in 1:250 dilution. 
3.7. Evaluation of immunostaining 
Staining for mycobacterial antigen MPT64 was evaluated with light microscopy. Staining with the 
previous anti-MPT64 pAb was used as a comparison for intensity and pattern of staining. Criteria 
for selection of positive signals were based on localization of MPT64 antigen signal intracellularly 
in macrophages, epithelioid cells, or giant cells of granulomatous lesions or extracellularly in 
necrotic areas. The intensity of IHC staining of sections was evaluated based on the researcher’s 
subjective assessment and categorized as either weak, moderate, or strong. Criteria for NSS were 




3.8. Clinical samples for validation 
Human clinical biopsies were used for the validation of the new anti-MPT64 pAb. Formalin-fixed 
paraffin-embedded biopsies from lymph nodes and cell blocks made from pleural effusions were 
used. These materials were collected as part of another project where the clinical samples were 
obtained from a cohort of EPTB patients. Patients of all ages with presumptive TB attending Gulab 
Devi Hospital outpatient clinics for enlarged lymph nodes or pleural effusion were interviewed. 
Patients with no history of TB treatment were enrolled (after providing informed consent) from 
April 2016 to August 2017. Patients were excluded if they had a history of TB treatment during 
the previous year. For patients with pleural effusions, fluids were aspirated using a 50 ml syringe. 
Excision biopsy was performed for patients with enlarged lymph nodes. Immediately, the biopsy 
specimen was divided into two. One half of the biopsy was placed in 10 ml of physiologic (0.9%) 
saline for bacteriology. The other half of the biopsy was placed in buffered formalin for histology 
examination. The biopsy specimen in physiologic saline was minced in a manual sterile tissue 
homogenizer (15 ml; 19 × 155 mm) and then transferred to a sterile 50 ml centrifuge tube. The 
pleural fluid specimen (35–45 ml) was transferred directly to a centrifuge tube. Then, specimens 
were centrifuged (3000 × g for 15 min) without decontamination and the sediment was used for 
smear, GeneXpert (Cepheid, Sunnyvale, CA, USA), and culture. Auramine O-stained smears were 
examined using a light emitting diode fluorescence microscope (83). Two slopes of Löwenstein-
Jensen medium and one Mycobacteria Growth Indicator Tube (MGITe 960e; Becton Dickinson, 
Sparks, MD, USA) were inoculated for culture (84). GeneXpert was performed according to 
manufacturer protocols (85).  
For patients with pleural effusions, cell blocks were prepared. The sample was centrifuged within 
one hour after aspiration. The supernatant was discarded, and the deposit was mixed with 10% 
formalin. The quantity of formalin was 10 times the quantity of deposit. The mixture was incubated 
for overnight fixation. After that, the sample was centrifuged. The supernatant was discarded, and 
the deposit was placed on filter paper. The filter paper was then placed in a cassette. Paraffin blocks 




3.9. Ethical clearance 
The study protocol was approved by the Regional Committee for Medical and Health Research 
Ethics, Western-Norway (REK Vest), and the National Bioethics Committee of Pakistan 
(Islamabad, Pakistan). 
3.10. Data management and statistical Analysis 
The data was entered into Microsoft Excel and descriptive statistics were applied. To compare the 
differences in categorical variables, the Chi-square test was used. P-value ˂ 0.05 was considered 
statistically significant. A two by two table was used to calculate Sensitivity, specificity, positive 
predictive value, negative predictive value, and accuracy by using the bacteriological confirmation 
by culture and/or GeneXpert (Cepheid, Sunnyvale, CA, USA) as a reference method.  
4. Results 
4.1. Testing of individual sera with enzyme-linked immunosorbent assay  
Sera from all bleeds gave very good results with ELISA. The titer was mostly around 1:200.000, 
which was the highest titer measured. As shown in Table 2, the titer results are homogenous, with 
only one exception that is not shown. 
4.2. Testing of individual sera with immunohistochemistry 
The sensitivity of pAbs with IHC was not as good as in ELISA. Most of the sera gave reactivity 
with non-specific targets in biopsies like fibrous tissue or smooth muscles, etc. This made it 
difficult to interpret the positive results. By dilution of the sera, this challenge was overcome to a 
large extent, and it was possible to differentiate specific staining (SS) from the NSS (Table 2). 








Table 2. The result of the individual sera from all bleeds of 25 rabbits tested with 
immunohistochemistry with different dilutions on TB biopsies and their ELISA titer. 
FOOTNOTE. ELISA, enzyme-linked immunosorbent assay; IHC, immunohistochemistry; SS, specific staining; 
NSS, non-specific staining; B, bleed. 
Tried dilutions Results Working dilutions
500 Strong SS &weak NSS
1000 Weak SS & no NSS
500 Strong SS & weak NSS
1000, 2000 No staining
500 Strong SS & weak NSS
600 Strong SS & no NSS
1000 Weak SS & no NSS
2000 NO staining
500 Strong SS & weak NSS
600 No staining
1000 Strong SS & strong NSS                                                                                                                                                                                           
2000 Weak SS & no NSS
4000 No staining
1000  Strong SS & moderate NSS
2000 Weak SS & weak NSS
Short, 1 1: 200000 1000 Weak SS & strong NSS No optimal
1000 Strong SS &moderate NSS
2000 Weak SS & no NSS
1000 Strong SS & strong NSS
2000 Weak SS & moderate NSS
Short, 1 > 1: 200000 1000  Moderate SS & Strong NSS No optimal
Long, 3 1:200000 500 B1: Strong SS & weak NSS B1: 500
500 &1000 B1,2&3: Strong SS & moderate NSS
2000 B1,2&3: Moderate SS& no NSS
B1: No staining
B2 &B3: Strong SS & no NSS
500 B1,2&3: Strong SS & moderate NSS
600 B1,2 & 3: Moderate SS & moderate NSS
1000 & 2000 B1,2 & 3: No staining
500 B1: Strong SS & strong NSS
600 B1: Weak SS & Strong NSS
500 B1: Strong SS & no NSS
600 B1: Weak SS & no NSS
500 & 600 B1,2 & 3: Strong SS & moderate NSS
1000 B1,2 & 3: Weak SS & moderate NSS
500 B1: Strong SS & NSS B1: No optimal
B1: Moderate SS & moderate NSS
B2 &3:Strong SS & weak NSS
1000 & 2000 B1,2&3: Weak SS & weak NSS
B1 & 2: Weak SS & weak NSS
B3: Moderate & strong NSS
500 B1,2 & 3: Strong SS & moderate NSS                                                                                                                                                                                                                                             
1000 B1,2 & 3: Strong SS &no NSS
2000 B1,2 & 3: Weak SS & no NSS                                                                                                                                                                                                                                                                
B1: Strong SS &weak NSS B1 &3: 200
B2: Weak SS & weak NSS
B3: Moderate SS & weak NSS
B1: Moderate SS &no NSS
B2: Weak SS & NSS
B3: Weak SS & no NSS
B1: Weak SS & no NSS
B2: No staining
B3: Weak SS &no NSS
Long, 3 >1: 200 000 1000 & 2000 B1,2 &3: Strong SS & no NSS B1,2&3: 2000
B1:  No staining B1: No optimal
B2 & 3:  Moderate SS & no NSS B2 & 3: 1000
1000 B1,2 & 3: Strong SS & Strong NSS
2000 B1,2 & 3: Strong SS & moderate NSS
B1: Strong SS & moderate NSS B1&3: No optimal
B2: Moderate SS & no NSS
 B3: Strong SS & Strong NSS
500 & 600 B1,2 &3: Strong SS &no NSS
B1 & 3: No staining
B2: Weak SS & no NSS
2000 B1,2 & 3: No staining
Long, 3 >1: 200 000 1000
Long, 3 1:200 000 B1,2&3: 600
1000
B2:1000
Long, 3 >1: 200 000 1000
Long, 3 >1: 200 000 No optimal
Long, 3 > 1: 200000 B1,2 & 3: 1000





Long, 3 1: 200000
600
B2 &3: 600
Long, 3 1: 200000 1000 B1, 2 & 3: No optimal
Long, 3 1: 200000 B1: 500
Long, 3 1: 200000 No optimal
Long, 3 1: 200000 No optimal
Long, 3 1: 200000 No optimal
Short, 1 > 1: 200000 No optimal
Long, 3 1: 200000
B1: 2000
4000 B2&3: 4000
Short, 1 > 1: 200000 No optimal
Short, 1 > 1: 200000 1000
Short, 1 1: 200000 500
Short,1 > 1: 200000 No optimal
Short, 1 1: 200000 500
Short, 1 1: 200000 600
Immunization protocol, bleeds per rabbit ELISA titer
IHC
Short, 1 1: 200000 500
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4.3. Testing of cocktails with immunohistochemistry 
Based on the performance of the individual sera on the biopsies, a strategy was designed to pool 
the sera from various rabbits and bleeds. Table 3 shows the results from various cocktails. Cocktail 
3 gave the best sensitivity and specificity and was selected as the functional pAb. Figure 5 shows 
the staining with cocktail 3. Cocktails 1, 4, and 5 gave NSS and were not further validated on the 
clinical samples. Cocktail 2 gave very good results but was not validated further due to the lower 









Figure 5. Immunohistochemistry staining of anti-MPT64 polyclonal 
antibodies (cocktail 3) in 1:400 dilution on lung biopsy with 
tuberculosis pneumonia. Signals are seen as reddish-brown granular 
staining against a blue hematoxylin background. 
35 
 
Table 3. Staining results with polyclonal antibody cocktails with immunohistochemistry on 
biopsies using different dilutions. 
FOOTNOTE. SS, specific staining; NSS, non-specific staining; C3 400, cocktail 3 in 1:400 dilution; C3 800, 
cocktail 3 in 1:800 dilution; C4 800, cocktail 4 in 1:800 dilution; C4 1600, cocktail 4 in 1: 1600 dilution 
 
4.4. Strategies to reduce non-specific staining with immunohistochemistry 
Table 4 shows the results of various strategies used to reduce the non-specific binding of pAbs. A 
positive TB biopsy and a non-TB biopsy were used for IHC. Incubation of biopsies with a 
combination of 3% bovine serum albumin and 10% normal goat serum by overnight incubation 
was the best strategy and it significantly reduced the NSS. Otherwise, all the other strategies did 
not work. The purification of pAbs with antigen affinity purification was not successful as it 
reduced the SS indicating that the epitopes in vivo in the formalin-fixed biopsies are different from 
the epitopes on the antigen used in the column, and the specific antibodies were lost during the 
process of purification. Even though the non-specific reactivity was with the various normal 
structures in the biopsies, the absorption of pAbs with non-TB lung and lymph node biopsies did 
not specifically reduce the NSS. There was an overall reduction in reactivity with both specific 
Positive control ( lung TB biopsy) Negative control ( non-TB lymph node biopsy)
5, 10, 20, 40, 50,80 &100 Strong NSS Strong staining
200 Moderate SS & strong NSS Strong staining
400 Weak SS & moderate NSS Moderate staining
800 No SS & weak NSS Weak staining
1600 No staining No staining
50 Strong NSS Strong staining
100 Moderate SS & moderate NSS Moderate staining
200 Moderate SS & weak NSS Strong staining
400 Strong SS & no NSS Weak staining
50 & 100 Strong NSS Strong staining
200 Strong SS & moderate NSS Moderate staining
400 Strong SS & weak NSS Weak staining
800 Weak SS & no NSS No staining
1600 No staining No staining
50, 100 & 200 Strong NSS Strong staining
400 Weak SS & Strong NSS Strong staining
800 Weak SS & moderate NSS Moderate staining
1600 No SS & weak NSS Weak staining
C3 400 + C4 800 Moderate SS & strong NSS Strong staining















and non-specific targets. Increasing the incubation time with serum-free protein block or using a 
pure Fc receptor blocker did not reduce the NSS either. Mixing the pAbs sera with sodium 
thiocyanate reduced both specific and non-specific reactivity. Mixing with betaine solution had no 
effect. 
Table 4.  Results of various strategies used to reduce the non-specific staining of polyclonal 
antibodies with immunohistochemistry. 
Strategy Results  
PAbs + antigen affinity purification  Significantly reduced SS & NSS 
PAbs + BCG Copenhagen vaccine strain Moderate reduction of the intensity of SS, 
and no additional reduction of NSS 
PAbs + formalin-fixed paraffin-embedded non-
TB lung and lymph nodes biopsies 
Moderate reduction of the intensity of SS, 
and no additional reduction of NSS 
Sections + serum-free protein block for 12, 30 
and 60 minutes, and overnight 
SS unaffected, no reduction in NSS 
Sections+ 60 minutes with 3% bovine serum 
albumin +10% normal goat serum, followed by 
60 minutes serum-free protein block 
SS unaffected, reduction in NSS  
Sections + overnight 3% bovine serum albumin + 
10% normal goat serum followed by 12 minutes 
serum-free protein block  
SS unaffected, significant reduction in 
NSS 
Sections + human Fc block pure SS unaffected, no reduction in NSS 
PAbs + betaine solution No reduction in NSS 
PAbs + sodium thiocyanate  Significantly reduced SS & NSS 
FOOTNOTE. PAbs, polyclonal antibodies; BCG, Bacillus Calmette-Guérin; TB, tuberculosis; NSS, non-specific 
staining; SS, specific staining,  
 
4.5. Validation of polyclonal antibodies on clinical samples 
4.5.1. Patients characteristics 
A total of 86 clinical samples were used for the diagnostic validation of pAbs. The 
bacteriologically confirmed TB cases with positive culture and/or Xpert were selected. Table 5 
shows the characteristics of 45 patients from where the TB samples were collected. There were 
gender differences with a predominance of females among patients with lymphadenitis and males 
among pleuritis (p= 0.000). The median age was similar between the two groups. There was no 
statistically significant difference in systemic symptoms between the two groups. The majority 
(90%) of the lymph nodes biopsies had typical histological findings of necrotizing granulomatous 
inflammation consistent with TB. The majority (87%) of the pleuritis patients had minimal or 
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moderate amounts of effusion and only 13% had massive amounts. The appearance and the 
biochemistry of the pleural fluid were consistent with tuberculous effusion with unilateral effusion 
in 87%,  the predominance of lymphocytes and high protein content >3g/dl. 
Forty-one non-TB biopsies with various diagnoses including Reactive lymph nodes, Ovarian 
Papillary carcinomas, Fibroadenoma, Benign Prostatic hyperplasia, Leiomyoma, Hydrocele, 
Chronic tonsillitis, Corpus luteum, Myometrium-normal, Breast Carcinoma, were used as negative 
controls. 




TB pleuritis P-value5 
Age years median (range) 20 (5-44) 25 (15-70)  
Sex 
Male n/N (%) 
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Lymphocyte % median (range) 
 





Histopathology n/N (%) 
Necrotizing Granulomatous 
Inflammation 








FOOTNOTE. TB, tuberculosis; n, number, N, Total number; %, percentage; NA, not available. 
1Characteristics: Denominator is different as information was not complete for all cases. 
2Fever was the most frequent systemic symptom.  
3Local symptoms include symptoms from the site of disease. 
4CXR= chest Xray. 
5P-value= comparison between lymphadenitis and pleuritis. 
 
 
4.5.2. Performance of new polyclonal antibody in comparison with the routine 
laboratory diagnostic tests, GeneXpert assay, and previous anti-MPT64 
polyclonal antibody. 
The results of all diagnostic procedures are shown in Table 6. Compared to the other tests, the new 
anti-MPT64 pAb test was positive in a higher proportion of specimens. The performance of the 
new anti-MPT64 pAb was similar to the previous anti-MPT64 pAb. In total, 86.6% of the TB cases 
were positive with the new anti-MPT64 pAb, compared to 6.6% with AFB microscopy, 76.2% 
with culture, and 60.2% with the GeneXpert. The proportion of AFB microscopy and GeneXpert 
positive cases were higher among lymphadenitis cases as compared to pleuritis, while the 
proportion of culture-positive cases was higher among pleuritis cases. Signals were detected in 
8/41 (19.5%) non-TB cases tested by the new anti-MPT64 pAb. 
Using culture-positive cases as the reference standard, the new anti-MPT64 pAb was compared 
with the GeneXpert assay.  New anti-MPT64 pAb was positive in 88.2% of the cases as compared 




Table 6. Results of different diagnostic tests in tuberculous lymphadenitis and pleuritis. 
Samples 
 
Number of specimens n/N (%) positive by 
AFB 
Microscopy  
LJ culture GeneXpert  New anti-
MPT64 pAb  
Previous anti-
MPT64 pAb 
Bacteriologically confirmed TB cases 
Lymph node 
(n=24) 
2/24 (8.3) 16/24 (66.7) 22/24 (91.7) 21/24 (87.5) 23/24 (95.8) 
Pleural fluid 
(n=21) 
1/21 (4.8) 18/21 (85.7) 6/21 (28.6) 18/21 (85.7) 14/21 (66.7) 
Culture confirmed TB cases  
 Lymph node 
(n=16) 
2/16 (12.5)  14/16 (87.5) 14/16 (87.5) 16/16 (100.0) 
Pleural fluid 
(n=18) 
1/18 (5.6)  3/18 (16.7) 16/18 (88.9) 12/18 (66.7) 
Non-TB cases* 
(n=41) 
Not done  Not done Not done  8/41(19.5) Not done 
FOOTNOTE.  n, number; N,Total number; %, percentage; LJ, Lowenstein-Jensen; TB, tuberculosis; pAb, 
polyclonal antibody; AFB, acid-fast bacilli. * Non-TB cases included: Reactive lymph node, Ovarian Papillary 
carcinoma, Fibroadenoma, Benign Prostatic hyperplasia, Leiomyoma, Hydrocele, Chronic tonsillitis, Corpus 
leuteum, Myometrium-normal, Breast Carcinoma. 
 
4.5.3. Staining pattern and comparison with previous anti-MPT64 polyclonal 
antibody 
MPT64 antigen was stained reddish-brown within the cytoplasm of macrophages, epithelioid cells 
(Figure 6), and sometimes in the multinucleated giant cells or extracellularly in necrotic areas 
(Figure 7). Intracellular staining varied in pattern from diffuse to granular. In the cell blocks, the 
signals were present intracellularly in the cells morphologically consistent with macrophages 
(Figure 8).  Compared to the previous anti-MPT64 pAb, the intensity of staining was less strong, 
and the NSS was more frequent (Table 7). However, it was possible to distinguish the specific 
signals from the NSS on the biopsies. The SS was localized in the TB lesions, and the intensity 
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was stronger, while the NSS was in the normal-looking structures where the TB lesions were not 
present.  
 
     
Figure 6. The staining pattern of new anti-MPT64 polyclonal antibody (a, c) and old anti-MPT64 polyclonal 
antibody (b, d) in tuberculous lymphadenitis from different lesions by immunohistochemistry. The positive 
signals are seen as reddish-brown granular staining (arrows) in the epithelioid cells of the lesions. Weak diffuse 







      
     
     
Figure 7. The staining pattern of new anti-MPT64 polyclonal antibody (a, c) and old anti-MPT64 polyclonal 
antibody (b, d) in tuberculous lymphadenitis from different lesions by immunohistochemistry. The positive 







    
Figure 8. The staining pattern of new anti-MPT64 polyclonal antibody (a, c, e) and old anti-MPT64 polyclonal 
antibody (b, d) in tuberculous pleuritis from different cell blocks by immunohistochemistry. The positive 







Table 7. Comparison of intensity of staining by previous anti-MPT64 and new anti-MPT64 
polyclonal antibodies by immunohistochemistry on tuberculous lymphadenitis and 
pleuritis specimens. 
FOOTNOTE. TB, tuberculosis; pAb, polyclonal antibody; None, no staining. Weak, moderate, and strong is based 
on the visual subjective criteria. 
 
4.5.4. Diagnostic validation of the new MPT64 polyclonal antibody 
The diagnostic validity of IHC with the new anti-MPT64 pAb, by using bacteriology confirmed 
(culture and/or GeneXpert) cases as a reference standard, showed the sensitivity of 88% and 86% 
for lymphadenitis and pleuritis cases, respectively with the corresponding specificity of 80% for 
both. Using the culture alone as the reference standard, the sensitivity of IHC with the new anti-
MPT64 pAb was 88% and 89%, while for GeneXpert was 88% and 17% in lymphadenitis and 
pleuritis, respectively (Table 8). The performance of new anti-MPT64 pAb was significantly better 
than GeneXpert in the TB pleuritis patients. AFB microscopy has the lowest sensitivity of 13% 
and 6% in TB lymphadenitis and pleuritis, respectively.  
  
TB Cases Number of positive cases according to intensity  
Previous anti-MPT64 pAb New anti-MPT64 pAb 
None Weak Moderate Strong None Weak Moderate Strong 
Lymphadenitis 1 8 6 9 3 10 11 0 
Pleuritis 7 3 5 6 3 15 3 0 
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Table 8.  Diagnostic validity of immunohistochemistry with new anti-MPT64 polyclonal 
antibody and GeneXpert.  
 Sensitivity 
% (95% CI) 
Specificity 






Bacteriological confirmation (culture and/or GeneXpert) as reference standard 
Lymphadenitis 
New anti-MPT64 pAb 
     
88 (68-97) 80 (65-91) 72 92 83 
Pleuritis 
New anti-MPT64 pAb 
     
86 (64-97) 80 (65-91) 69 92 82 
Culture as reference standard 
Lymphadenitis 
AFB microscopy  
GeneXpert  
New anti-MPT64 pAb 
     
13 (2-38)     
88 (62-98)     
88 (62-98) 80 (65-91) 64 94 82 
Pleuritis 
AFB microscopy  
GeneXpert  
New anti-MPT64 pAb 
     
6 (0-27)     
17 (4-41)     
89 (65-99) 80(65-91) 67 94 83 
     
FOOTNOTE. %, percentage; PPV, positive predictive value; NPV, negative predictive value; CI, confidence 
interval; AFB, acid-fast bacilli; pAb, polyclonal antibody. 
 
5. Discussion 
In this study, we have shown a strategy to successfully reproduce a large amount of functional pAb 
against an MTB complex specific antigen MPT64 for application in IHC as a diagnostic test for 
EPTB. We have previously shown that IHC-based MPT64 antigen detection test is robust, quick, 
and more sensitive as compared to the routine microbiological diagnostic tests (1-8). The main 
aim of this study was to reproduce the primary antibody in a large amount for large-scale use of 
the test. The results indicate that the sensitivity of the test by using the new pAb is comparable 
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with the previous pAb. However, the specificity seems to be less. Due to the small sample size, 
the results cannot be generalized yet. These pAbs are being tested on a larger clinical sample in an 
ongoing project, and the results from these studies will give better evidence for the diagnostic 
validity of the test.  
Previous studies have shown that this test is implementable in routine diagnostic settings in both 
high TB (3) and low TB (2) endemic settings. Furthermore, the technology of IHC is robust and 
widely available in most of the laboratories. AFB microscopy is quick and cheap, but it can only 
detect intact bacilli and it has very low sensitivity. IHC has an advantage over AFB microscopy 
that it can detect MTB antigen in fragmented bacilli as well, and it has thereby higher sensitivity. 
IHC has the potential to offer considerable improvement in the diagnosis of the most usually 
paucibacillary EPTB. Although culture is a gold standard for the definite diagnosis of EPTB, it is 
time- consuming and requires advanced laboratory facilities. IHC, on the other hand, is quick and 
has higher sensitivity. Both IHC and GeneXpert have high sensitivity and can give a result within 
a day or two. However, IHC has an advantage over GeneXpert in the sense that IHC is robust, 
probably cheaper, and does not require high tech equipment. One limitation of IHC is that it needs 
a trained pathologist for interpretation. Besides, GeneXpert sensitivity is variable in the various 
form of EPTB and is not recommended for all forms of EPTB (57-59).   
Another antigen detection test in TB is LAM detection in urine (62). This test is only applicable 
for the HIV positive pulmonary TB patients with a high load of antigen that is excreted in urine 
(61, 62, 65). This test is not applicable for other forms of TB with relatively low antigen load, 
particularly EPTB which is most often a paucibacillary disease with low antigen load in the 
circulation. On the contrary, the MPT64 test is applicable to a variety of extrapulmonary tissues. 
This high sensitivity of the MPT64 antigen detection test is probably due to the intracellular 
accumulation of antigen in the lesions (86). The relative high load of antigen at the site of infection 
as compared to the bacilli is the most plausible explanation for a remarkable high sensitivity of the 
test despite the paucibacillary nature of the disease.  
The production of mAbs would have been the ideal due to their high specificity and much less 
challenge with background and cross-reactivity (87, 88). Moreover, mAbs have minimal batch-to-
batch variation (88, 89). However, in our laboratory, efforts to produce a functional mAb for IHC 
application have not been successful. Our group was able to produce a mAb which works very 
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well in ELISA, but it does not give good results with IHC. This could be attributed to the loss of 
relevant clones during the selection process, as ELISA instead of IHC was used for the selection 
of the relevant clones. It was not feasible to have an IHC-based system of formalin-fixed material 
for selection of relevant clones. Therefore, we decided to produce functional pAb. There are 
several advantages of pAbs over mAbs. Compared to mAbs, the main benefits of pAbs  are 
attributed to two essential inherent features: clonal and biophysical diversity (89). The benefit of 
polyclonality is the possibility for pAbs to heterogeneously bind to multiple and different antigenic 
epitopes, resulting in higher sensitivity in certain assays. Especially in IHC, the pAbs can be a  
better option as the effects of tissue fixation and processing on epitopes are unknown and could be 
highly variable (89). The property of multiepitope binding of pAbs makes the antigen recognition 
possible even if some of these epitopes are affected by changes in the antigen structure (89, 90). 
On the other hand, mAbs may find their epitope buried, resulting in low sensitivity in detecting 
their antigens. It has also been reported for IHC that pAbs result in higher sensitivity when the 
antigens to be detected have low quantities in the sample (91). The biophysical diversity of pAbs 
results in greater stability when environmental challenges may lead to inactivation, lability or 
precipitation of other forms of antibodies (92). The storage and dilution of pAbs are in general 
easier than mAbs, due to the variation in their biophysical characteristics, such as charge and 
hydrophobicity. On the other hand, mAbs  usually needs the addition of stabilizing agents to avoid 
aggregation, precipitation, and maintain antibody binding (92). Compared to mAbs, pAbs are 
relatively more resistant to changes in temperature and pH. MAbs usually need stabilizers to 
preserve their biological activity when they are exposed to environmental changes (93). To 
overcome the issue of the batch-to-batch variation from different animals, we used the strategy of 
pooling the sera from several animals to make a cocktail in a large volume. This strategy seems to 
work, and the cocktail of various antisera is stable at 4C preserved by 0.02% Thimerosal and 
15mM sodium azide. 
 We chose rabbits for immunization as they were most easily and widely available due to their 
suitable size, easy to deal with and to collect blood samples, and have long life span. Besides, they 
are good source of sufficient production of high-titer antiserum with high-affinity (87).  
When the pAbs were tested by ELISA, they gave higher titer than when they later been tested with 
IHC. This can be explained by the adverse effects of formalin fixation of the tissue (89). Although 
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formalin fixation has many advantages, it can disrupt the 3-dimensional structures of antigen 
epitopes and weaken the ability of pAbs to detect the epitope. However, the polyclonality of pAbs 
resulting in high-avidity binding could increase the probability of antigen detection as compared 
to mAb (94, 95).  
One of the challenges we faced with pAbs was the non-specific reactivity on the biopsies. This is 
inevitable due to the polyclonality and multiepitope binding of the pAbs which one hand gives 
higher sensitivity but oftentimes leads to high cross-reactivity with other proteins that have almost 
similar structures, giving non-specific background staining. In our study, we have succeeded to a 
large extent to overcome this negative aspect of background staining by saturating the non-specific 
binding sites on tissue sections with overnight incubation with bovine serum albumin and normal 
goat serum followed by saturation with serum-free protein block containing 0.25% casein in 
phosphate-buffered saline for 12 minutes. These solutions, prior to application of primary 
antibody, helped to reduce the non-specific binding of pAbs to the undesired sites in the tissues 
like connective tissue, epithelial tissue, muscles, and adipocytes by binding to them. 
The negative controls in this study were selected from the archives. The criteria for selection was 
non-TB cases. These cases had not been tested for TB by culture or  GeneXpert. We could not run 
these tests as material was not suitable for these tests. Therefore, we could not calculate the 
specificity of GeneXpert when culture was used as a reference standard. However, the probability 
that these negative controls would have been positive by any of these tests is very low. Another 
limitation of this study is that we have not tested the new anti-MPT64 pAb on non-TB cell blocks 
to have a direct comparison with the pleural fluid cell blocks. Furthermore, we have not tested the 
new anti-MPT64 pAb on the fine-needle aspirates or cell smears. The interpretation of positive 
signals on fine needle aspirates or cell smears can be challenging due to the non-specific 
background staining. In biopsies, the specific signals can be differentiated from the background 
staining by selecting the lesion areas where the antigen is expected to be present and ignoring the 
NSS in irrelevant areas of the biopsy. Further validation of these pAbs is ongoing on a larger 
material which will address these limitations.  
In conclusion, we have shown that it is possible to reproduce pAbs which can detect the MPT64 
antigen in the formalin-fixed paraffin-embedded tissue sections by IHC. It is possible to make a 
single batch in a large volume by making a cocktail of various sera. This opens up the possibility 
48 
 
of the large-scale use of this test, and its inclusion in the routine diagnostics of EPTB as it has 
higher sensitivity than the routine diagnostic tests.  
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